← Back to Search

Lymphedema Prevention Strategies

N/A

Waitlist Available

Led By Simona Shaitelman

Research Sponsored by M.D. Anderson Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion, an average of 1 year

Awards & highlights

Study Summary

This trial is to see how breast cancer patients feel about being screened for lymphedema, and if they're happy with the program.

Who is the study for?

The PREVENT trial is for English-speaking breast cancer patients who've had axillary lymph node dissection. It includes those with preoperative measurements (Cohort I) and those within 0-6 months post-surgery intending to continue follow-up at MD Anderson (Cohort II). Patients unable to complete a questionnaire are excluded.Check my eligibility

What is being tested?

This study evaluates patient opinions on lymphedema screening, which detects swelling after breast cancer treatment. Cohort I receives annual screenings, while Cohort II has more intensive follow-ups. Patient satisfaction with the program is also assessed.See study design

What are the potential side effects?

Since this trial focuses on screening and opinion gathering rather than medical intervention, it does not directly involve side effects from treatments or medications.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through study completion, an average of 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through study completion, an average of 1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

To establish the effectiveness of prospective, intensive lymphedema screening in the postoperative setting using a perometer.

Trial Design

2Treatment groups

Experimental Treatment

Group I: Cohort II (patients followed intensively for lymphedema)Experimental Treatment1 Intervention

We will prospectively follow a cohort of 279 patients who have recently undergone ALND in this upcoming year with intensive lymphedema screening.

Group II: Cohort I (patients receiving annual lymphedema screening)Experimental Treatment1 Intervention

We will retrospectively retrieve information on patients who previously underwent preoperative perometer lymphedema screening during the past year who were treated definitively for their breast cancer with an ALND, and for whom no follow-up postoperative lymphedema screening was done.

Do I qualify?Apply below to find out